JP2020524167A - Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法 - Google Patents

Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法 Download PDF

Info

Publication number
JP2020524167A
JP2020524167A JP2019570568A JP2019570568A JP2020524167A JP 2020524167 A JP2020524167 A JP 2020524167A JP 2019570568 A JP2019570568 A JP 2019570568A JP 2019570568 A JP2019570568 A JP 2019570568A JP 2020524167 A JP2020524167 A JP 2020524167A
Authority
JP
Japan
Prior art keywords
cells
administered
subject
cell carcinoma
merkel cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524167A5 (enExample
Inventor
ハンス クリンゲマン
ハンス クリンゲマン
ティエン リー
ティエン リー
ローラン ボワセル
ローラン ボワセル
Original Assignee
ナントクエスト インコーポレイテッド
ナントクエスト インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナントクエスト インコーポレイテッド, ナントクエスト インコーポレイテッド filed Critical ナントクエスト インコーポレイテッド
Publication of JP2020524167A publication Critical patent/JP2020524167A/ja
Publication of JP2020524167A5 publication Critical patent/JP2020524167A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019570568A 2017-06-20 2018-06-19 Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法 Pending JP2020524167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522319P 2017-06-20 2017-06-20
US62/522,319 2017-06-20
PCT/US2018/038312 WO2018236890A1 (en) 2017-06-20 2018-06-19 Nk-92 cells and il-15 agonist combination therapy

Publications (2)

Publication Number Publication Date
JP2020524167A true JP2020524167A (ja) 2020-08-13
JP2020524167A5 JP2020524167A5 (enExample) 2021-09-30

Family

ID=62875319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570568A Pending JP2020524167A (ja) 2017-06-20 2018-06-19 Ｎｋ−９２細胞とｉｌ−１５アゴニストの併用療法

Country Status (9)

Country Link
US (1) US20200121720A1 (enExample)
EP (1) EP3641799A1 (enExample)
JP (1) JP2020524167A (enExample)
KR (1) KR20200017495A (enExample)
CN (1) CN110740747A (enExample)
AU (1) AU2018288715A1 (enExample)
CA (1) CA3066465A1 (enExample)
IL (1) IL270840A (enExample)
WO (1) WO2018236890A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220160479A (ko) * 2021-05-27 2022-12-06 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834257T2 (de) 1997-04-30 2007-01-04 Klingemann, Hans Natürliche killerzelllinien und verfahren zu ihrer verwendung
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
EP2388266B1 (en) 2007-05-11 2014-04-23 Altor BioScience Corporation Fusion molecules and IL-15 variants
JP6251570B2 (ja) 2010-09-21 2017-12-20 アルター・バイオサイエンス・コーポレーション 多量体ｉｌ−１５可溶性融合分子並びにその製造及び使用方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDREAS LUNDQVIST: "31ST ANNUAL MEETING AND ASSOCIATED PROGRAMS OF THE SOCIETY FOR IMMUNOTHERAPY 以下備考", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. VOL:4, NR:1, JPN5020007795, 16 November 2016 (2016-11-16), GB, pages 82, ISSN: 0004986164 *
CLINICALTRIALS.GOV ARCHIVE ＮＣＴ０２４６５９５７，［ＯＮＬＩＮＥ］, vol. retrieved from internet:, JPN6022027450, 9 June 2017 (2017-06-09), ISSN: 0004986163 *
MARTINS INES: "FDA names potential Merkel cell therapy, using aNK cells, an orphan drug", IMMUNO-ONCOLOGY NEWS [ONLINE], vol. retrieved from internet:, JPN6022027451, March 2017 (2017-03-01), ISSN: 0004986162 *
SHAILENDER BHATIA: "ADOPTIVE CELLULAR THERAPY (ACT) WITH ALLOGENEIC ACTIVATED NATURAL KILLER (ANK) CELLS 以下備考", [ONLINE], JPN5020007794, 9 November 2016 (2016-11-09), US, pages 1, ISSN: 0004986161 *

Also Published As

Publication number Publication date
AU2018288715A1 (en) 2019-12-12
WO2018236890A1 (en) 2018-12-27
CN110740747A (zh) 2020-01-31
KR20200017495A (ko) 2020-02-18
IL270840A (en) 2020-01-30
EP3641799A1 (en) 2020-04-29
CA3066465A1 (en) 2018-12-27
US20200121720A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
Grover et al. Myeloid-derived suppressor cells: a propitious road to clinic
Najafi et al. The current knowledge concerning solid cancer and therapy
Goldfarb et al. Surgery as a risk factor for breast cancer recurrence and metastasis: mediating mechanisms and clinical prophylactic approaches
JP2015505313A (ja) 癌を治療するための併用療法
Li et al. The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1–thymopentin fusion peptide and its binding to TLR2
US20170072038A1 (en) Combination therapy with wt1 peptide vaccine and temozolomide
CA3113552A1 (en) Immunogenic composition for the treatment of cancer
JP2009542623A (ja) Ｈ２遮断薬、少なくとも１つの抗炎症薬剤および細胞毒性薬剤を含む抗がん治療
CN112972688A (zh) PPARδ抑制剂联合免疫治疗药物在制备抗肿瘤药物中的应用
Meron et al. PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity
US20240342211A1 (en) Short-term activated dc1s and methods for their production and use
JP2011506436A (ja) 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
US9463198B2 (en) Compositions and methods for reducing or preventing metastasis
WO2020259477A1 (en) Small molecule inhibitors for treating cancer in a subject having tumors with high interstitial pressure
Avraham et al. Synergism between immunostimulation and prevention of surgery-induced immune suppression: an approach to reduce post-operative tumor progression
JP2020524164A (ja) Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法
JP2022551672A (ja) 乳癌治療法
US20230233474A1 (en) Use of mrnas encoding ox40l, il-23 and il-36gamma for treating cancer
US20200121720A1 (en) Nk-92 cells and il-15 agonist combination therapy
US20190290776A1 (en) Non-adult human dosing of anti-cd30 antibody-drug conjugates
Cayssials et al. Beyond tyrosine kinase inhibitors: Combinations and other agents
Dyevoich et al. Type I IFN, Ly6C+ cells, and phagocytes support suppression of peritoneal carcinomatosis elicited by a TLR and CLR agonist combination
EP4302833A2 (en) Compositions for modulating pd-1 signal transduction
US9757457B2 (en) Use of 2-deoxy-D-glucose to sensitize cancer cells to an agent that activates the extrinsic apoptotic pathway
HK40021263A (en) Nk-92 cells and il-15 agonist combination therapy

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210611

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210611

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230209